177Lu-PSMA after surgery or radiation for high-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new treatment called 177Lu-PSMA given after standard therapy (surgery or radiation) to see if it can prevent prostate cancer from coming back. It is for patients with high or very high-risk prostate cancer that hasn't spread yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high or very high-risk prostate cancer that was diagnosed by biopsy.
- You finished your main prostate cancer treatment (surgery or radiation) within the past 3 months.
- Recent scans (within the last 28 days) show no signs that the cancer has spread to other parts of your body.
- You have castrate testosterone level (your hormones are suppressed, usually by medication).
- Your bone marrow, liver, and kidneys are working well, checked by blood tests.
- If you are able to father children, you must agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
This trial tests a radioactive drug (lutetium) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if it can shrink the tumor and improve outcomes.
This study looks at patients treated with a radioactive drug called 177Lu-PSMA-617 for a type of prostate cancer that has spread, stopped responding to hormone therapy, and has been treated with chemotherapy. It checks how the treatment affects the body and the tumor using images.
This trial compares two radioactive drugs (177Lu-PSMA-617 and 225Ac-PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that has not spread far. The goal is to see which drug is better at shrinking the tumor and reducing the chance of cancer coming back.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.